Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) announced on August 18 that it has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics, for aggregate cash consideration of 76 crore rupees, or roughly $7.95 million. The purchase brings Piramal’s total ownership of Yapan Bio to 74%, converting it from an associate company, a minority holding, into a consolidated subsidiary, and the deal closed on the same day it was announced.

From Associate to Subsidiary

Piramal has actually held a stake in Yapan Bio since 2021; based on the numbers in the release, that earlier stake works out to roughly 33%, though the company does not restate that prior figure directly. The distinction between associate and subsidiary status matters beyond semantics: as a subsidiary, Yapan Bio’s revenue, costs, and balance sheet will now be fully consolidated into Piramal’s financial statements going forward, rather than showing up only as a smaller equity-method line item, which is a real change to how the business shows up in Piramal’s reported financials even though the underlying operations are the same ones Piramal has already been working alongside for several years.

What Yapan Bio Does

Yapan Bio provides process development, characterization, and Phase I and II GMP manufacturing services for vaccines and biologics, essentially acting as an outsourced lab and manufacturing partner for drugmakers who do not want to build that specialized capacity themselves. That outsourcing model, known as a CDMO, is common across the biologics industry because biologic manufacturing requires highly specialized, capital-intensive facilities that many drug developers, particularly smaller ones, cannot justify building in-house for a single program. Owning rather than simply partnering with a biologics CDMO gives Piramal more direct control over capacity planning, quality systems, and pricing for that part of its service offering, compared with relying on a minority-owned associate whose decisions it could influence but not fully direct.

The ADCelerate Connection

Piramal says Yapan Bio also directly supports ADCelerate, a fixed-price, integrated platform Piramal Pharma Solutions offers to move a customer’s antibody-drug conjugate (ADC) program from research through GMP manufacturing in as little as 12 months. An ADC is a cancer treatment that chemically links a targeting antibody to a cell-killing drug payload, combining the specificity of an antibody with the potency of a small-molecule drug; developing and manufacturing that kind of hybrid molecule is more complex than either a conventional biologic or a conventional small-molecule drug alone. The 12-month timeline is Piramal’s own stated service commitment rather than an independently verified benchmark, and the release does not disclose how many ADC programs have actually moved through ADCelerate on that schedule.

What the Company Is Saying

Peter DeYoung, CEO of Piramal Global Pharma, said the investment supports the company’s long-term growth and its ability to meet rising global demand for complex biologics, framing the deal as extending patient access to needed therapies; that is the company’s own characterization of the deal’s ultimate benefit rather than a measured outcome. The Yapan Bio subsidiary will continue operating within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of Piramal Pharma Limited, rather than being run as a separate standalone unit.

Part of a Broader Industry Trend

This is part of a broader pattern of large CDMOs acquiring or absorbing specialized biologics capacity as demand grows for outsourced manufacturing of biologics, cell and gene therapies, and ADCs, categories that are generally more technically demanding to manufacture than traditional small-molecule pills. Global pharmaceutical and biotech companies have increasingly relied on CDMOs for these more complex modalities rather than building the specialized facilities themselves, since the capital and regulatory expertise required can be difficult to justify for a single drug program, particularly for smaller biotech companies without an existing manufacturing base. Consolidating a long-held associate into a fully owned subsidiary, as Piramal has done here, is a lower-risk way to expand that kind of capacity compared with acquiring an entirely unfamiliar company, since Piramal has already worked alongside Yapan Bio’s operations and management for roughly five years and presumably has direct visibility into its quality systems and performance.

Piramal’s Broader Business

Piramal describes itself as operating 17 global development and manufacturing facilities with distribution into more than 100 countries, spanning three main businesses: Piramal Pharma Solutions, the CDMO business that Yapan Bio now sits within; Piramal Critical Care, a hospital generics business; and a consumer healthcare business selling over-the-counter products. The company also holds a stake in Abbvie Therapeutics India Private Limited, a joint venture with AbbVie that Piramal describes as a market leader in ophthalmology treatments in India, though that venture is unrelated to this transaction.

What’s Next

No information on Yapan Bio’s current revenue, headcount, or facility capacity was disclosed in the release, and none is estimated here. This article covers a completed corporate acquisition and is not an investment recommendation.

Sources

Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited, PRNewswire, August 18, 2026.

Editorial Disclosure

This article is based on a press release issued by Piramal Pharma Solutions on August 18, 2026, distributed via PRNewswire. Piramal Pharma Limited trades on the National Stock Exchange of India under the ticker PPLPHARMA and on the Bombay Stock Exchange under the code 543635. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the strategic benefits of the acquisition, service timelines, and future demand for biologics manufacturing are forward-looking or company-sourced characterizations rather than independently verified findings. This article is for informational and educational purposes only and does not constitute investment advice. See our full DISCLAIMER.